CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

You are here

Products

back to search results

CD16 [DJ130C]

Product group: Primary
Monoclonal/ Polyclonal: Monoclonal
Clone: DJ130C
Host: Mouse
Application: Flow cytometry (FC), Immunofluorescence (IF), Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blot (WB)
Application notes: Prediluted
Conjugation Type: Unconjugated
Reactivity: Human
General notes: Localization: membrane, secreted.
Buffer: citrate pH6.0 or EDTA pH8.0
UNSPSC code: 12352203

CD16 is a biomarker associated with monocytes and natural killer (NK) cells of the lymphoid lineage. Anti-CD16 immunohistochemistry is useful in differentially diagnosing hepatosplenic gamma delta T-cell lymphoma and gamma delta T-cell large granular lymphocyte leukemia from other peripheral T-cell lymphomas, such as mucosal and cutaneous gamma delta T-cell lymphoma. It is reported that 58% of hepatosplenic gamma delta T-cell lymphomas express CD16, and 86% of gamma delta T-cell large granular lymphocyte leukemias are immunoreactive with anti-CD16. Mucosal and cutaneous gamma delta T-cell lymphomas usually do not express CD16 antigen. A significant decrease can be seen in the number of granulocytes expressing CD16 in chronic myelomonocytic leukemia compared to chronic myelogenous leukemia and control bone marrow biopsy, probably related to dysgranulopoiesis. Bone marrow biopsy immunohistochemistry can be helpful in CMML by identifying both the monocyte expansion and the dysgranulopoies

CD16 [DJ130C]

CD16 is a biomarker associated with monocytes and natural killer (NK) cells of the lymphoid lineage. Anti-CD16 immunohistochemistry is useful in differentially diagnosing hepatosplenic gamma delta T-cell lymphoma and gamma delta T-cell large granular lymphocyte leukemia from other peripheral T-cell lymphomas, such as mucosal and cutaneous gamma delta T-cell lymphoma. It is reported that 58% of hepatosplenic gamma delta T-cell lymphomas express CD16, and 86% of gamma delta T-cell large granular lymphocyte leukemias are immunoreactive with anti-CD16. Mucosal and cutaneous gamma delta T-cell lymphomas usually do not express CD16 antigen. A significant decrease can be seen in the number of granulocytes expressing CD16 in chronic myelomonocytic leukemia compared to chronic myelogenous leukemia and control bone marrow biopsy, probably related to dysgranulopoiesis. Bone marrow biopsy immunohistochemistry can be helpful in CMML by identifying both the monocyte expansion and the dysgranulopoiesis with anti-CD16.